GGrantIndex
Sort

16,179 grants matching malaria

Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in Africa

$727,306
Philip Jon Rosenthal · University Of California, San Francisco · R01 · FY2021 · AI

Epidemiology and determinants of emerging artemisinin-resistant malaria in Ethiopia

$727,267
Jonathan Boyd Parr · Univ Of North Carolina Chapel Hill · R01 · FY2023 · AI

Artemisinin Resistance in Africa: its emergence and evolution in Rwanda

$727,201
Jeffrey A. Bailey · Brown University · R01 · FY2022 · AI

Lead Optimization of DHODH Inhibitors for Malaria

$726,917
Margaret A. Phillips · Ut Southwestern Medical Center · R01 · FY2021 · AI

BIODIVERSITY CONSERVATION &DRUG DISCOVERY IN MADAGASCAR

$726,469
Virginia Polytechnic Inst And St Univ · U01 · FY2004 · TW

BIODIVERSITY CONSERVATION &DRUG DISCOVERY IN MADAGASCAR

$726,467
Virginia Polytechnic Inst And St Univ · U01 · FY2005 · TW

Midgut mitochondrial function as a driver of resistance and fitness in mosquitoes

$726,380
Michael Allen Riehle · University Of Arizona · R56 · FY2018 · AI

Evaluating the role of P53 pathways in malaria

$726,260
Tuan Manh Tran · Indiana University Indianapolis · R01 · FY2024 · AI

Functional Biology Of T Cells

$726,148
Ronald Germain · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI

Analysis of Host-Pathogen Interactions

$726,148
Ronald Germain · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI

VIOLIN 2.0: Vaccine Information and Ontology LInked kNowledgebase

$725,992
Yongqun He · University Of Michigan At Ann Arbor · U24 · FY2025 · AI

Fosinopril analogs for the treatment of human babesiosis

$725,898
Choukri Ben Mamoun · Yale University · R01 · FY2022 · AI

Fosinopril analogs for the treatment of human babesiosis

$725,898
Choukri Ben Mamoun · Yale University · R01 · FY2023 · AI

Fosinopril analogs for the treatment of human babesiosis

$725,898
Choukri Ben Mamoun · Yale University · R01 · FY2024 · AI

Fosinopril analogs for the treatment of human babesiosis

$725,898
Choukri Ben Mamoun · Yale University · R01 · FY2025 · AI

IMMUNE REGULATION AND VACCINE DEVELOPMENT IN LEISHMANIASIS

$725,877
David Sacks · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI

Importation and transmission of malaria in Zanzibar: a case study for elimination

$725,478
Jonathan J Juliano · Univ Of North Carolina Chapel Hill · R01 · FY2021 · AI

Intervening to Improve Birth Weight and Infant Respiratory Health in Rural Ghana

$725,300
Patrick Lott Kinney · Columbia University Health Sciences · R01 · FY2011 · ES

Orally Bioavailable 4(1H)-Quinolones with Multi-Stage Antimalarial Activity

$725,226
Roman Manetsch · Northeastern University · R01 · FY2019 · AI

Multi-Omics Characterization of Plasmodium Vivax Hypnozoites

$725,059
David Serre · University Of Maryland Baltimore · R01 · FY2023 · AI

Optimization of antimalarials targeting multiple life stages of the parasite

$724,987
Paul R Carlier · University Of Illinois At Chicago · R01 · FY2022 · AI

Mechanisms of effective antibody neutralization

$724,692
Niraj Tolia · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI

Structural characterization of host-pathogen interactions

$724,692
Niraj Tolia · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI

Tfh responses to novel vaccine candidates and protection from pediatric falciparum malaria

$724,615
Jonathan D. Kurtis · Brown University · R01 · FY2017 · AI

Epidemiology and determinants of emerging artemisinin-resistant malaria in Ethiopia

$724,281
Jonathan Boyd Parr · Univ Of North Carolina Chapel Hill · R01 · FY2024 · AI